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H

ypoglycemia is responsible for approximately

hypoglycemia. In addition, individuals with type 1

100 000 emergency room visits per year in

and type 2 diabetes that are treated with intensive

the United States at a cost of about $120 000 000.1

insulin therapy are at increased risk for severe

The American Diabetes Association (ADA) defines

hypoglycemia.1

hypoglycemia as a condition characterized by
abnormally low blood glucose levels, usually less
than 70 mg/dl.
While all hypoglycemia is of concern, mild
to moderate hypoglycemia typically does not
constitute an emergency and can be treated by
the individual with the ingestion of a quick-acting
simple carbohydrate.1 Treatment examples include
glucose tablets or gel, regular juice or soda,
sugar, honey, or candy such as gummy bears or
jellybeans.
Treatment of severe hypoglycemia requires
assistance from others and is considered a
medical emergency. If unconsciousness or the
inability to eat or drink occurs, glucagon may be
administrated by injection to raise the glucose
levels to normal. Glucagon, a hormone produced
by the pancreas, stimulates the liver to produce
and release stored glucose into the bloodstream.
Risk factors for severe hypoglycemia include
length of time living with diabetes, impaired
awareness, and previous episodes of severe

Glucagon Kits Are a Necessity
The ADA recommends that people with diabetes
have an immediate source of glucose to treat
mild or moderate hypoglycemic episodes and
a prescription glucagon kit for the treatment
of severe hypoglycemic episodes. Instructing

While the safety of

patients on the risk, avoidance, and treatment of

glucagon administered

hypoglycemia is a core component of Diabetes

by trained non-medical

Self-Management Education.
Injectable glucagon kits are available as a

personnel is well estab-

medication to treat severe hypoglycemia. While

lished, the treatment has

the safety of glucagon administered by trained

been reported to be

non–medical personnel is well established, the
treatment has been reported to be underutilized.

2

Approximately 25% of people with type 1

underutilized.

diabetes have impaired hypoglycemia awareness
and are more likely to experience severe
hypoglycemia requiring assistance from a third
party.3 Yet the lack of an in-date glucagon kit has

The lack of an in-date

been shown to be a common area of deficiency in

glucagon kit has been

the care of insulin pump patients.4
Patients need to have a hypoglycemia
emergency plan in place. This includes a trained
caregiver who can correctly assess the situation,

shown to be a common
area of deficiency in

knows where the glucagon kit is kept, and

the care of insulin pump

understands the proper administration of the life-

patients..

saving medication.
Investigating Glucagon Access and Utilization
The team at the Diabetes Center of Excellence
(DCOE) at Joint Base San Antonio-Lackland
undertook a quality improvement project to
investigate the accessibility and use of glucagon
among its patients. The goal of the project was to
assess if patients had an emergency plan in place
consisting of:
1. a current prescription for glucagon
2. availability of the glucagon
3. someone trained to administer it in the time
of need.
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The team targeted type 1 patients (insulin pump

Survey Results Show Improvements

or multiple daily injections) and type 2 patients

A total of 218 patients were surveyed in 2013 and

using insulin pumps. Patients were identified

200 patients in 2015. Approximately two-thirds

and screened each day prior to their clinic

(67.4%) of the patients in 2013 and 57% in 2015

appointments. Clinic staff recorded answers to the

utilized insulin pump therapy, and the remaining

following survey questions:

patients used multiple daily injections (MDI) to

Do you have glucagon in your home? Yes or No

administer insulin. There were 132 patients who

■

Is it expired? Yes, No, or Don’t know

participated in both surveys.

■

Have you had a hypoglycemic event that
required assistance? Yes or No

2013 and 2015 surveys. There was a significant

■

Who was taught to use glucagon? You, Family

increase in the presence of glucagon kits in the

member, Other, No one

home from 2013 to 2015. However, there was no

■

Figure 1 compares patient responses to the

significant difference in the percentage of patients

Completed forms were given to providers for

that had either expired glucagon at home or did

review. Providers were then required to complete

not know whether it was expired or not. A smaller

the bottom of the form answering the following

percentage of patients affirmed the presence of

questions:
■

Did you review this form?

■

Did you order glucagon?

in-date glucagon.
The percentage of family members trained
to administer glucagon increased significantly,

This process was projected to continue for 12

from 50.8% in 2013 to 79.7% in 2015 (Figure 2).

months. Initial data were collected primarily during

The percentage of patients educated in glucagon

2013. The process was repeated for 7 months in

administration also increased, from 66.2% to 83.2%.

2015. The same target population was used.

Only 1.5% of patients in 2015 reported that no one
knew how to use glucagon.

100%

2013

94.5%

2015

90%
80%

74.3%

Breakdown of Glucagon in Home

70%
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Figure 1. Comparison of patient reported glucagon in the home in 2013 and 2015.
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Figure 2. Comparison of glucagon trained people in 2013 and 2015.

hypoglycemia. A note in the convenience file alerts

An addition to the

of Defense (DoD) tends to be transient, the 132

staff to address the need for initiating or renewing

individuals who participated in both surveys and

the glucagon prescription, generating or updating

patient convenience

those who participated only in 2013 or in 2015

the emergency plan, and educating friends or

files now tracks all

were examined as subgroups to see if the data

family members on how to administer glucagon in

patients identified as

reflected a change as a result of the intervention

the event of a severe hypoglycemic reaction.

Since the patient population in the Department

or of other confounding factors associated with
the improvement. Results were very similar to the

training and for home reference. Glucagon

overall population; thus, the team inferred that

training kits were obtained from both Lilly and

the observed improvement was the result of the

Novo Nordisk and are used in the clinic. Patients

intervention.

also learn about a free smartphone app created

Increasing Staff Awareness
As this project progressed, it became clear that
providers assumed that insulin pump patients and
patients with type 1 diabetes had glucagon readily

regimen, which places
them at risk for severe
hypoglycemia.

by Lilly that provides virtual training on how to
administer glucagon and a reminder system to
alert patients about updating a glucagon kit that is
soon to expire.

available and a plan in place to receive it in the

Addressing the Fear Factor

event of a severe hypoglycemic reaction. It was

During training sessions, it was noted that many

also assumed that patients would contact the clinic

support people had a fear of needles and of giving

when a new prescription was needed.

shots. This challenge was addressed by offering

The 2013 survey showed a need to increase

using an intensive insulin

A patient handout was developed to facilitate

in-clinic training for the support person. It was also

staff awareness and incorporate an ongoing

recommended that the patient teach the support

method for addressing hypoglycemia and the need

person how to check blood glucose levels and

for glucagon in the patient population. An addition

have the person assist in administering insulin.

to the patient convenience files now tracks all
patients identified as using an intensive insulin
regimen, which places them at risk for severe
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Familiarization with the diabetes equipment and
the injection technique during a nonstressful

instructed to call 911 for help and reassurance.
Adult learners and children are instructed

time was felt to increase the support person’s

on proper glucagon storage, preparation, and

confidence should they be needed to help during

injection. They are taught that glucagon may be

an emergency.

administered almost anywhere on the body, and

Many patients stated that there were only
children in the home, and most underestimated
the abilities of a young person to recognize

it’s emphasized that it may be injected through the
clothes if needed.
Some patients lived alone and had no friends

hypoglycemia symptoms and administer

or family to rely on for glucagon administration.

emergency glucagon if needed. Children as

These patients received contact information for

young as 7 years of age have been taught how

local companies that provide emergency home

to administer glucagon and when to call 911. The

monitoring systems and were encouraged to

administration of glucagon may ordinarily omit

identify and consider other options for support as

the need for emergency assistance, but this step

well (eg, neighbors, church members, coworkers).

was included in the instruction for children. The
average response time for glucagon is 13 minutes.5
Since the wait can seem long to a child, they are

Other Learning
Upon implementation of the project, we
realized we did not consider some of the costrelated issues. Within the DoD, medications
are predominantly provided by the Military
Treatment Facility (MTF) pharmacy. The
pharmacies maintain an inventory based on past
and present utilization and budget accordingly.
We neglected to inform the pharmacy of our
project, and as a result, the supply of glucagon
was quickly depleted, which brought about
unexpected cost increases to the facility.
DoD beneficiaries receive medications at little
or no co-pay, but the cost of glucagon to nonDoD beneficiaries could be prohibitive for some
patients. An online cost comparison suggests the
estimated cash price is about $244 to $271. Even
with insurance, a patient may have a substantial
co-pay; many patients report paying about $100
out of pocket. For patients experiencing financial
hardship, the glucagon manufacturer has a patient
assistance program.

There are some interesting new
delivery systems for glucagon
on the horizon.
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Manufacturers of glucagon state that the
medication has a shelf life of 24 months; however,
that does not mean the patient is receiving a kit
that will not expire before two years. A kit may
be in pharmacy storage for some time before
the patient fills the prescription. Therefore, it is
important for patients and family members to be
aware of the expiration date on their glucagon kit
and request a new one before it expires.
There are some interesting new delivery
systems for glucagon on the horizon. For example,
in trials, a nasal spray containing powdered
glucagon was shown to be highly effective in
treating severe hypoglycemia.5 Since it does not
require mixing and needles are not involved,
it may be easier for a third party to administer.
Even though it took longer to take effect (16 vs
13 minutes for the injection), it took less time to
administer (16-26 seconds vs 1.9-2.4 minutes for
the injection).5
Conclusion
Tracking glucagon availability and training may
be an important intervention to increase safety
for those at risk for severe hypoglycemia. This
simple project can be replicated in other clinics to
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